Background: New bone metabolic markers have become available clinically for evaluating chronic kidney disease mineral and bone disorders (CKD-MBD). e aim of this study was to correlate these new bone metabolic markers with conventional markers in regular hemodialysis (HD) patients.
Dysregulation of mineral and bone metabolism occurs frequently in chronic kidney disease (CKD), causing increased risk of cardiovascular disease (CVD) [1, 2] . High CVD morbidity and mortality are observed to link with hyperphosphatemia, the calcium-phosphorus product (Ca × P) and secondary hyperparathyroidism (SHPT) [3, 4] .
e Kidney Disease Outcomes uality Initiative (K/DOQI) of the US National Kidney Foundation introduced practice guidelines for bone metabolism and disease in CKD, recommending tight control of serum calcium (Ca), phosphorus (P), Ca × P and intact parathyroid hormone (iPTH) levels [5] . In addition to the role these markers play in bone metabolism, they also contribute to the progression of vascular calci cation, leading to high mortality by CVD in hemodialysis (HD) patients [3, 4, 6] .
e mechanisms of CKD mineral and bone disorders (CKD-MBD) are not fully understood; both traditional and nontraditional CKD and CVD risk factors are thought to contribute to CKD-MBD.
Bone remodeling is an ongoing cyclical process and is characterized by two di erent activities: bone formation and bone resorption. Clinically, several di erent biochemical markers are used to diagnose CKD-MBD, make follow-up of HD patients and initiate appropriate treatment. Several studies have shown that bone formation and bone resorption markers are well correlated with progression of CKD-MBD in HD patients [7] . Among those markers, the most frequently used is bone-speci c alkaline phosphatase (BAP). e increased levels of iPTH are not always synonymous with high turnover bone disease, probably because iPTH secretion is dependent on serum Ca and P levels and because iPTH is not a direct marker of bone remodeling. Serum BAP concentration is reportedly more sensitive than iPTH and osteocalcin (OC) in distinguishing the type of bone disease and estimating bone formation rate [8] . It is unclear whether nontraditional markers for bone remodeling are more useful than traditional markers for better maintenance of CKD-MBD in HD population.
To clarify the issue, new bone metabolic markers were correlated with conventional markers for KD-MBD. Two bone formation markers, BAP and OC, and one bone resorption marker, amino-terminal telopeptides of type 1 collagen (NTx), were measured. Serum levels of the new markers were also compared in two groups that were divided by serum iPTH levels, according the K/DOQI guidelines.
Patients and Methods
Subjects e cross-sectional study enrolled 143 patients who were all undergoing HD therapy in our center. e causes of CKD included diabetes mellitus (37.8%), renal sclerosis (2.8%) and chronic glomerulonephritis (52.4%). An additional thirteen patients were excluded from the study, either because they were treated with more than one blood puri cation therapy during the three month regime or because they were medically unstable.
e patients were treated with stable HD therapy over a three month period, using the same type of membrane and the same dialysis procedure. HD was performed with single-use hollow-ber dialyzers equipped with modi ed cellulose-based or polysulfone membranes. Maintenance HD was carried out for 3-4 h each session, three times a week with a blood ow rate of 150-220 ml/min and with a dialysate ow rate of 500 ml/ min. Dialysate contained Na + (140 mmol/l), K + (2.0 mmol/l), Ca 2+ (1.5 mmol/l), and HCO 3 -(30 mmol/l). Ninety-one patients were treated with anti-hypertensive medications including angiotensin-converting enzyme inhibitors (16 patients), angiotensin receptor blockers (56 patients), calcium antagonists (51 patients), β-blockers (13 patients), α-blockers (7 patients), and diuretics (19 patients). 1α(OH)D3 was used in 52 participants. e study was approved by all local medical ethics committees and all patients gave informed consent before inclusion.
Data collection
Hematological and biochemical blood samples were collected a er at least 10 h of fasting just prior to the rst HD session of week and tested at the laboratory at our center. e levels of BAP, OC and NTx were measured by enzyme immunoassay, immunoradiometric assay and enzyme-linked immunosorbent assay, respectively, (SRL, Inc.,Tokyo, Japan) [9] [10] [11] . Blood pressure (BP) was measured hourly during HD session using a mercury sphygmomanometer. Mean levels of systolic and diastolic BP were determined as the means of measurements obtained in eight di erent midweek HD sessions in which patients showed essentially the same increase in body weight [12] .
Statistical Analysis
All the results are showed as mean ± standard deviation (SD). Two sided t-tests and Mann-Whitney U analyses were used to compare parametric and non-parametric data, respectively. e data were expressed as mean values ± SD. Analyses exploring Takano et al. Bone mineral markers in HD patients the relationship between PDV levels and variables were performed using the Pearson correlation test. A P-value of <0.05 was considered statistically signi cant. Table 1 shows characteristics of the participants of the study. Serum levels of intact PTH showed no signi cant correlation with serum levels of Ca, P or Ca × P, indicating that the circulating level of iPTH is an independent factor from the three variants in the study (Fig. 1) . Next, the degree of correlation between the four bone turnover markers, Ca, P, Ca × P and iPTH, and the four bone turnover markers was evaluated. Neither alkaline phosphatase (ALP) nor BAP showed a strong correlation with the bone turnover markers (Table 2 ). e serum levels of NTx and OC showed relatively good correlation with the serum levels of iPTH, but no correlation with the serum levels of Ca, P or the Ca × P (Fig. 2) . ese data suggest that the circulating levels of NTx and OC could give additional information about SHPT in CKD population under HD therapy.
Results
e new bone turnover markers were then evaluated to determine whether they changed independently. e levels of NTx and OC have a strong positive correlation, although they are markers of di erent processes: bone formation and resorption, respectively (Table 2 ). e levels of ALP show a positive correlation only with the serum levels of BAP but not with . Relationship between circulating intact parathyroid hormone (iPTH) and serum calcium (Ca), phosphorus (P) and calcium-phosphorus product (Ca x P) levels in uremic patients before dialysis treatment. FIGURE 2. Relationship between circulating intact parathyroid hormone (iPTH) and serum amino-terminal telopeptides of type 1 collagen (NTx), osteocalcin (OC) and bone-speci c alkaline phosphatase (BAP) levels in uremic patients before dialysis treatment. NTx or OC (Table 2) . Serum BAP levels show weak, positive correlation with serum NTx and OC levels ( Table 2) . ese results suggest that a combination of serum OC and NTx levels could give useful information about CKD-MBD in HD patients and that the imbalance of serum NTx and OC levels may re ect the pathological status of bone metabolism in HD patients even though the molecules are markers of di erent bone metabolic/catabolic processes. e K/DOQI guidelines recommends that serum levels of iPTH should be controlled to within 150-300 pg/mL in HD patients [5] . To determine whether the three bone markers show signi cant di erences between two groups, HD patients were divided into two groups according to their serum iPTH levels (Table 3) . e high iPTH group shows signi cantly higher levels of the three bone markers compared with the low or normal iPTH group (Table 4) . Both bone formation and resorption markers show the same tendency: that the high iPTH group exhibits higher levels of two bone markers than the low iPTH group. is suggests that the three bone markers are as useful indicator of SHPT as the conventional markers such as ALP and iPTH. Discussion e correlation among four new mineral bone markers and conventionally used markers was examined in HD patients at a single center. A recent study indicated that therapeutic interventions associated with excessive lowering of parathyroid activity favor low bone turnover or adynamic bone disease, in turn leading to the progression of arterial calci cation [13] . Serum levels of ALP usually increase in CKD-MBD, especially in high-turnover bone disease [14, 15] . Although serum iPTH levels are frequently used as a marker for bone remodeling, serum ALP seems a more reliable marker of severity of the highturnover bone disease than increased iPTH levels, because circulating serum ALP originates directly from pathologic bone; however,. Consistent with this notion, Palmer et al. reported that treatment of CKD-MBD using vitamin D analogs can e ectively decrease serum levels of ALP, even though such a treatment does not consistently decrease serum PTH levels [16] . In spite of the usefulness of ALP in high-turnover Low iPTH levels:<300 pg/ml; high iPTH levels: >300 pg/ g/ml Low iPTH levels:<30 00 pg/ml; high iPT TH levels: >300 pg/ /ml bone disease, there appears to be a requirement for novel bone markers to evaluate low-turnover or adynamic bone disease. Newly available bone markers have little information regarding their usefulness for evaluating CKD-MBD, even though there are many publications about the properties of each marker. ere are also few reports examining the relationships among the various markers. ree compounds, BAP, NTx and OC, have been selected for this study because of their potential as markers of bone metabolism/disease. An added advantage to studying these particular compounds is that their measurement is currently covered under Japan's national health insurance system. .
BAP is known as a stable molecule, not in uenced by either renal dysfunction or the HD procedure because it is exclusive metabolized in the liver. Serum BAP concentration alone provides useful information about the rate of bone remodeling in HD patients [17] . Combining measurement of both serum iPTH and BAP levels improves the sensitivity, speci city, and predictive value in the diagnosis of the type of bone turnover [14] . With high values of serum BAP or iPTH, there is little correlation between these two markers even when serum iPTH levels are 100 pg/ml [8] . Our data suggest that circulating OC and NTx levels could be more strongly correlated with serum iPTH levels than with serum BAP levels. In other words, BAP may not be suitable for diagnosing SHPT. Our data suggest that serum OC and NTx levels could be more strongly correlated with serum iPTH even when iPTH levels are relatively high. One explanation is that BAP is more suitable marker for the adynamic status of bone; thus, a dissociation between serum iPTH and BAP levels becomes clear in high-turnover bone disease [18] . Our data are not totally consistent with a previous report from Takahashi et al. [7] , in which serum BAP levels are more strongly correlated with NTx than serum PTH levels. Both studies were performed as cross-sectional studies, but characteristics of HD patients were quite di erent, especially with respect to the duration of HD and age of participants. e characteristics of HD patients may a ect the status of CKD-MBD, leading to di erent levels of circulating bone markers. Bone mineral density is used to evaluate bone quality, but bone mineral density is unsuitable as an index for assessing the e ect of therapeutic intervention to treat CKD-MBD because, although the gold standard for evaluating the state of bone metabolism is bone biopsy, repeated biopsies are inadvisable because they are invasive. A combination of these markers could be an adequate index for monitoring bone metabolism.
e combination of OC and NTx could give precise information about bone metabolism because serum levels of these two markers showed more signi cant correlation with increase of serum PTH in HD patients. Another new nding of this study is that many HD patients show good correlation between bone formation and resorption markers even when the patients were treated with 1α(OH)D3 or phosphorus binders. Inbalance of these two markers could be a suggestion of pathological state of bone metabolism and warrants further study. e main limitation of the study is its cross-sectional design. Another important limitation of the study is the lack of bone biopsies, which are only performed in specialized centers.
e strength of the study is the uniform laboratory measurements, with all laboratory data obtained from a single facility.
In conclusion, serum OC and NTx levels are here shown to be as reliable as iPTH or BAP levels for evaluation of bone turnover in HD patients. Serum OC and NTx levels show good, positive correlation even though they are markers for di erent aspects of bone metabolism (bone formation and bone resorption).
erapeutic interventions in CKD-MBD could alter the serum levels of these biomarkers, and such effects need to be shown in future clinical trials.
